CytomX Therapeutics, Inc. 8-K

What Happened CytomX Therapeutics, Inc. (CTMX) filed an 8-K on June 22, 2026 reporting results from its June 17, 2026 Annual Meeting. Stockholders approved a Certificate of Amendment to increase authorized common shares from 300,000,000 to 600,000,000. Stockholders also approved amendments to the company’s equity plans: the 2015 Equity Incentive Plan was increased by 6,500,000 shares and the Employee Stock Purchase Plan was increased by 1,000,000 shares. The Board had adopted both plan amendments in March 2026 and they became effective upon shareholder approval.

Key Details

• Record date and turnout: 217,702,919 shares outstanding as of April 20, 2026; 183,604,084 shares were voted at the Annual Meeting.
• Charter amendment vote (Proposal 3): FOR 178,362,995; AGAINST 4,771,689; ABSTAIN 469,400.
• 2015 Plan amendment (Proposal 4): FOR 147,079,951; AGAINST 1,745,001; ABSTAIN 180,010; broker non-votes 34,599,122.
• ESPP amendment (Proposal 5): FOR 147,375,197; AGAINST 1,468,576; ABSTAIN 161,189; broker non-votes 34,599,122.
• Governance/audit items: Directors Matthew P. Young and Elaine V. Jones, Ph.D. were elected (Young FOR 146,742,827; Jones FOR 131,377,301). Ernst & Young LLP was ratified as the company’s independent auditor for FY2026 (FOR 182,976,052). An advisory vote on executive compensation passed and stockholders signaled they prefer annual say-on-pay votes.

Why It Matters Approving the charter amendment and equity plan increases gives CytomX legal capacity to issue many more shares (authorized common shares doubled to 600M) and expands the pool of shares available for employee compensation and stock purchase programs. That can support hiring, stock-based pay and future financings or transactions, but could also result in dilution if and when new shares are issued. Re-election of directors and ratification of the auditor are routine governance outcomes that maintain continuity at the board and audit levels.